Contact Us

NIH – Workshop on Expanding AAV Manufacturing Capacity for Rare Disease

CBM has large AAV Production and Manufacturing Capabilities

January 29, 2020

Cell & Gene Therapy CDMO Begins Operations

CBM offers process development, plasmid DNA, viral vectors, cell banking and cell processing


The Discovery Labs and Deerfield Management Company have formed The Center for Breakthrough Medicines, a contract development and manufacturing organization (CDMO). The CDMO is occupying over 40 percent (680,000 sq. ft.) of The Discovery Labs’ 1.6 million square foot biotech, healthcare and life sciences campus in King of Prussia, PA.

The CDMO provides preclinical through commercial manufacturing of cell and gene therapies and component raw materials. It offers process development, plasmid DNA, viral vectors, cell banking, cell processing, and support testing capabilities all under one roof. The company said the $1.1 billion facility will provide instant capacity as the largest known single source for accelerating the delivery and affordability of lifesaving and life-changing therapies from the bench to the patient’s bedside…

Read full story

January 27, 2020

Main Line Developer Plans to Build World’s Largest Cell and Gene Therapy Manufacturing Facility in King of Prussia

CBM's cell and gene therapy manufacturing facility is based in King of Prussia


Main Line developer Brian O’Neill is planning to build a $1.1 billion cell and gene therapy manufacturing facility as part of the Discovery Labs complex in King of Prussia, writes Katie Park for The Philadelphia Inquirer.

The Center for Breakthrough Medicines will claim 680,000 square feet of the 1.6 million-square-foot, biotechnology, health-care, and life sciences office complex.

The goal of the new facility is to pursue cures for various diseases in cooperation with scientists, pharmaceutical companies, and academic and governmental institutions…

Read full story

January 26, 2020

Main Line Developer Plans to Build World’s Largest Cell and Gene Therapy Manufacturing Facility in King of Prussia

CBM's cell and gene therapy manufacturing facility is based in King of Prussia

Main Line developer Brian O’Neill is planning to build a $1.1 billion cell and gene therapy manufacturing facility as part of the Discovery Labs complex in King of Prussia, writes Katie Park for The Philadelphia Inquirer.

The Center for Breakthrough Medicines will claim 680,000 square feet of the 1.6 million-square-foot, biotechnology, health-care, and life sciences office complex.

The goal of the new facility is to pursue cures for various diseases in cooperation with scientists, pharmaceutical companies, and academic and governmental institutions…

Read full story

A cell and gene therapy development center is taking 680K square feet at KOP’s Discovery Labs

At the Bio International Convention held last year in Philadelphia, The Discovery Labs announced it was opening 1.6 million square feet of coworking space and collaborative labs for healthcare, life sciences and tech companies out of GlaxoSmithKline’s former campus in King of Prussia.

About half a year later, nearly all its square footage has been accounted for, Audrey Greenberg, executive managing director of the Discovery Labs, told Technical.ly.

Included is a big get for the region: The Discovery Labs and Deerfield Management Company have formed The Center for Breakthrough Medicines, a contract development and manufacturing organization and specialty investment company, the Discovery Labs announced this week.

The Center for Breakthrough Medicines leased 680,000 square feet of Discovery Labs’ facility to provide pre-clinical through commercial manufacturing of cell and gene therapies, including process development, plasmid DNA, viral vectors, cell banking, cell processing and support testing capabilities…

Read full story

January 24, 2020

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

Manufacturing remains a major hurdle for companies pursuing gene and cell therapies, and as more products make it to market, the bottleneck could create problems with commercial supply.

At least seven manufacturing deals and site launches in January underscore different techniques companies and academics are employing in order to break through the capacity constraints for gene and cell therapies.

MANUFACTURING TEAMWORK

On Thursday, Deerfield Management and The Discovery Labs launched a contract development and manufacturing organization that will provide preclinical through commercial manufacturing of cell and gene therapies, as well as component raw materials…

Read full story

Real estate group creating $1.1B gene therapy CDMO at former GSK site

The real estate impresario that built a chain of upscale drug recovery facilities is now jumping on a new trend. Brian O’Neil’s MLP Ventures says it is creating a CDMO and building a $1.1 billion gene and cell treatment manufacturing operation in a former GlaxoSmithKline site near Philadelphia.

The Center for Breakthrough Medicines will be located at The Discovery Labs, the 1.6 million-square-foot bioscience co-working space MLP is developing in the former GSK facilities is slated to occupy about 40% of that space. MLP has partnered with Deerfield Management Company on the project.

The Discovery Labs chairman is Marco A. Chacón, who last year sold his Paragon Bioservices gene therapy CDMO to Catalent for $1.2 billion…

Read full story

January 23, 2020

Philly-area developer Brian O’Neill to build cell and gene manufacturing facility in King of Prussia

Brian O’Neill, the Main Line developer who founded the substance-abuse treatment chain Recovery Centers of America, plans to develop a $1.1 billion cell and gene therapy manufacturing facility in King of Prussia.

The company, which O’Neill has named the Center for Breakthrough Medicines, is part of the Discovery Labs, a 1.6 million-square-foot, $500 million biotechnology, health-care, and life sciences office complex he is building in an industrial section of King of Prussia. The center will claim 680,000 square feet of the Discovery Labs.

The goal of the center, its management said Wednesday, is to pursue cures for diseases including cystic fibrosis, hemophilia A, and certain cancers by working with scientists, large pharmaceutical companies, and academic and governmental institutions…

Read full story

The Center for Breakthrough Medicines is Building the World’s Largest Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) to Launch in King of Prussia, PA


The Discovery Labs and Deerfield Management Company have formed The Center for Breakthrough Medicines, a Contract Development and Manufacturing Organization (CDMO) and specialty investment company, to alleviate the critical lack of capacity that is preventing patients from accessing critically needed cell and gene therapies. The CDMO is occupying over 40 percent of The Discovery Labs’ 1.6 million square foot biotech, healthcare and life sciences campus in King of Prussia, PA…

Read full story

January 22, 2020